CITIC CLSA Raises Fosun Pharma Price Target, Keeps Outperform Rating
CITIC CLSA raised its price target for Fosun Pharma and maintained an Outperform rating.
Related stories
BLDR Reports Fiscal Q3 Profit Down 97.75%
BLDR reported fiscal third-quarter profit attributable to shareholders down 97.75% year over year, with basic EPS also reported.
M impact | EQUITY | Oct 30, 2026, 06:21 AM UTC
Global Dominion names new chairman and CEO
M impact | EQUITY | Oct 30, 2026, 06:20 AM UTC
AEDAS Homes Proposes Delisting Shares From Spanish Exchanges
M impact | EQUITY | Oct 30, 2026, 06:19 AM UTC
HSBC raises GE Vernova to Buy from Hold
M impact | EQUITY | Oct 30, 2026, 06:19 AM UTC
ResMed Publishes Q1 FY2027 Earnings Call Transcript
ResMed published a transcript of its Q1 fiscal 2027 earnings call.
M impact | EQUITY | Oct 30, 2026, 06:15 AM UTC
Microsoft Prices $25 Billion Senior Unsecured Notes Offering
Microsoft announced pricing for $25 billion in aggregate principal amount of senior unsecured notes.
H impact | EQUITY | Oct 30, 2026, 06:12 AM UTC